Scholar Rock (NasdaqGS:SRRK) FY Conference Transcript

Scholar Rock (NasdaqGS:SRRK) FY Conference Summary Company Overview - Scholar Rock is focused on developing innovative therapies targeting muscle-related diseases, particularly Spinal Muscular Atrophy (SMA) through its anti-myostatin pipeline, including the drug apitegromab [3][4] Key Value Creation Milestones - The company anticipates a transformative year in 2026 with the expected regulatory approvals for apitegromab in the US and Europe, aiming to establish a commercial presence in 50 countries [4][19] - Plans to develop apitegromab and a second myostatin inhibitor, SRK-439, for various severe and rare neuromuscular disorders [5][6] Regulatory and Manufacturing Updates - The initial launch of apitegromab was expected in 2025 but faced delays due to compliance issues at the manufacturing facility in Indiana, owned by Novo Nordisk [12][13] - The FDA granted a priority review for the drug, with an action date of September 22, 2025, but a complete response letter was received due to manufacturing facility compliance issues [12][14] - Positive progress has been made in remediating the facility, with a successful Type A meeting with the FDA and ongoing inspections [16][17] - The company is also preparing a second fill-finish facility to ensure supply chain robustness, which could support a 2026 launch even if the Indiana facility inspection does not go as planned [18][45] Market Opportunity and Pricing Strategy - Scholar Rock sees a multi-billion dollar opportunity in the SMA market alone, with a patient population of approximately 35,000 globally [6][50] - Pricing strategy will consider the rarity and severity of SMA, the impact of the drug on motor function, and the competitive landscape of existing therapies [51][52] Launch Strategy and Patient Engagement - The company expects robust demand for apitegromab, particularly from patients currently on therapy, with over 90% of trial participants remaining in long-term studies [53][54] - Initial launch uptake may be tempered by prior authorization requirements and medical policies from payers, but the company is optimistic about converting enrollment forms into reimbursed patients over time [56][57] Future Developments - Scholar Rock is also exploring a subcutaneous formulation of apitegromab and a next-generation myostatin inhibitor, SRK-439, which shows promise in early trials [58][61] - The company has initiated a Phase 2 study for Facioscapulohumeral Muscular Dystrophy (FSHD), with plans to dose patients later this year [64][65] Conclusion - Scholar Rock is positioned to become a significant player in the biotech space with its innovative therapies targeting muscle diseases, particularly SMA, while navigating regulatory challenges and preparing for a robust market entry in 2026 [4][19][56]